Edition:
United States

Stratec Biomedical AG (SBSG.DE)

SBSG.DE on Xetra

58.75EUR
23 May 2017
Change (% chg)

€-0.20 (-0.34%)
Prev Close
€58.95
Open
€59.47
Day's High
€59.66
Day's Low
€58.75
Volume
123
Avg. Vol
13,163
52-wk High
€61.23
52-wk Low
€41.30

Latest Key Developments (Source: Significant Developments)

Stratec Biomedical Q1 sales up at 49.5 mln euros
Thursday, 4 May 2017 01:36am EDT 

May 4 (Reuters) - Stratec Biomedical AG ::Q1 sales rose 58.6 percent to 49.5 million euros ($53.93 million).Dividend 0.77 euros per share.Sales of 49.5 million euros in Q1/2017 (+58.6%; Q1/2016: 31.2 million euros).Adjusted EBIT margin of 13.9% in Q1/2017 (Q1/2016: 14.5%).Q1 in consolidated net income of 5.4 million euros(+56.8%; previous year: 3.4 million euros).An update to financial forecast is expected to be released upon publication of half-yearly financial report on July 25, 2017.Until then, existing forecast remains valid..  Full Article

Stratec Biomedical FY consolidated net income up at EUR 25.4 mln
Thursday, 20 Apr 2017 01:35am EDT 

April 20 (Reuters) - Stratec Biomedical AG ::FY sales rose 25.9 percent to 184.9 million euros ($198.32 million).FY consolidated net income of 25.4 million euros (+14.9%; previous year: 22.1 million euros).  Full Article

Stratec Biomedical hikes dividend after 2016 profit gain
Tuesday, 14 Mar 2017 02:33am EDT 

Stratec Biomedical AG : FY sales rose 25.9 percent to 184.9 million eur . Dividend 0.77 eurper share versus 0.75 eurper share year ago . FY EBIT of eur 32.2 million. (+19.7%; previous year: eur 26.9 million) . FY EBIT margin at 17.4%. (previous year: 18.3%) . An update of financial guidance figures is expected to be released upon publication of half-year financial report on July 25 .Until then, existing guidance remains valid.  Full Article

Aixtron to return to TecDAX index, replacing Stratec Biomedical
Friday, 3 Mar 2017 04:07pm EST 

Deutsche Boerse :Says shares in Aixtron to replace Stratec Biomedical on TecDAX index.  Full Article

Stratec sees sales rising to 205-220 mln euros in 2017
Thursday, 21 Jul 2016 01:47am EDT 

Stratec Biomedical AG : Sees 2016 sales at eur 175 million to eur 182 million . Sees 2017 sales at eur 205 million to eur 220 million . Q2 (organic) sales +2.6% to eur 36.3 million (Q2/2015: eur 35.5 million) . Q2 saw recognition of non- recurring items, amounting to eur 1.4 million . Sales are expected to rise to between eur 205 million and eur 220 million, with a slight increase in ebit margin compared with 2016 . Q2 (organic) EBIT margin at 17.5% (Q2/2015: 17.3%) .2017 sales are expected to rise to between eur 205 million and eur 220 million, with a slight increase in ebit margin compared with 2016.  Full Article

Stratec Biomedical to propose dividend of 0.75 euro per share
Monday, 11 Apr 2016 08:24am EDT 

Stratec Biomedical AG:Board of Management and Supervisory Board approved the recommendation submitted by the Board of Management to propose the payment of a dividend of 0.75 euro per share for FY 2015.  Full Article

Stratec Biomedical to acquire hematology system specialist Diatron
Wednesday, 23 Mar 2016 04:38pm EDT 

Stratec Biomedical AG:To acquire hematology system specialist Diatron.Parties have agreed to maintain confidentiality concerning the purchase price.  Full Article

Stratec Biomedical lowers FY 2016 and FY 2017 forecast
Tuesday, 15 Mar 2016 06:50pm EDT 

Stratec Biomedical AG:2016 sales forecast of between 150 million euros and 154 million euros.New target for average sales growth between 2014 and 2017 now amounts to around 6 pct.2016 EBIT margin should remain stable.FY 2016 sales estimate 167.09 million euros - Thomson Reuters I/B/E/S.FY 2017 sales estimate 183.34 million euros - Thomson Reuters I/B/E/S.  Full Article

Stratec Biomedical confirms FY 2015 outlook and through to FY 2017 forecast
Wednesday, 28 Oct 2015 02:31am EDT 

Stratec Biomedical AG:Confirms forecast for 2015, expects to generate slight year-on-year sales growth at around growth rates reported to date in 2015.FY 2015 EBIT margin is expected to be above the level reported for the nine-month period.Confirms valid mid-term financial forecast.Sees average annual sales growth of eight to twelve percent through to 2017 based on the figures for the 2013 financial year (128.0 million euros) and for this to be accompanied by increasing profitability.FY 2014 sales 144.86 million euros.FY 2015 sales estimate 152.95 million euros - Thomson Reuters I/B/E/S.FY 2016 sales estimate 169.90 million euros - Thomson Reuters I/B/E/S.FY 2017 sales estimate 189.78 million euros - Thomson Reuters I/B/E/S.  Full Article

Stratec Biomedical AG comments on FY 2015 outlook
Wednesday, 22 Jul 2015 08:00pm EDT 

Stratec Biomedical AG:Ongoing positive development expected for financial year as a whole.Expect to generate slight sales growth in second half of 2015, accompanied by EBIT margin at current level.  Full Article

More From Around the Web

BRIEF-Stratec Biomedical Q1 sales up at 49.5 mln euros

* Q1 sales rose 58.6 percent to 49.5 million euros ($53.93 million)